Serum albumin-treated sn-38 prodrug nanoparticles toward cancer treatment

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Carrier-free drug nanoparticles are emerging as a next generation of drug delivery systems. Herein, we worked on improving their dispersion stability in the physiological environment by employing serum albumin protein. With anticancer SN-38 prodrug nanoparticles (NPs) and bovine serum albumin (BSA) as model studies, it was found that BSA prevented SN-38 NPs from aggregating in phosphate buffered saline, and the resulted nanoparticle dispersion becomes stable while maintains their anticancer efficiency.

Original languageEnglish
Pages (from-to)1555-1558
Number of pages4
JournalChemistry Letters
Issue number8
Publication statusPublished - 2021 Aug


  • Dispersion stability
  • Prodrug nanoparticles
  • Serum albumin


Dive into the research topics of 'Serum albumin-treated sn-38 prodrug nanoparticles toward cancer treatment'. Together they form a unique fingerprint.

Cite this